Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Delcath Systems, Inc.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Delcath Systems,
                                     Inc.

PR Newswire

NEW YORK, May 3, 2013

NEW YORK, May 3, 2013 /PRNewswire/ --Attorney Advertising --Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Delcath Systems, Inc. ("Delcath" or the
"Company") (NasdaqCM: DCTH). The investigation focuses on whether the Company
and its executives violated federal securities laws.

On May 2, 2013, shares of the Company plunged in after hour trading after an
FDA Advisory Committee voted 16-0 against recommending the company's Melblez
kit therapy for treatment of hepatic-dominant metastatic ocular melanoma. In
the FDA staff briefing released on Tuesday, reviewers noted that "substantial
and severe toxicity" was identified in the clinical trials, with seven percent
of the 122 patients treated by the drug-device combination dying as a result
of treatment related side effects. The company failed to disclose all these
risks and other material issues in its Phase 3 trials to investors. DCTH
shares have fallen $.99 to $.40 (-71%) since the time the FDA Advisory
Committee disclosed its briefing documents and ultimately held its vote.

If you are aware of any facts relating to this investigation, or purchased
shares of Delcath, you can assist this investigation by contacting Peretz
Bronstein of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
info@bgandg.com. Those who inquire by e-mail are encouraged to include their
mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration.Attorney advertising. Prior results do not guarantee similar
outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
info@bgandg.com

SOURCE Bronstein, Gewirtz & Grossman, LLC
 
Press spacebar to pause and continue. Press esc to stop.